The Magazine for Sleep Professionals
Wednesday, July 29, 2026
Kingman Strohl, MD Obstructive sleep apnea (OSA) is effectively managed by positive airway pressure (PAP) applied to the nose and/or mouth. The principle of PAP is to inflate the critical region of closure in the upper airway, usually at the base of the tongue or the uvula. The effective property […]
Somnics Inc. announces that the U.S. Food and Drug Administration (FDA) has granted clearance for the company’s groundbreaking capability to change the negative pressure setting of the iNAP Sleep therapy device. This innovative feature will significantly enhance the success of OSA treatment and empower physicians to titrate the device using […]
Sommetrics, a private company developing solutions to improve sleep health by providing innovative first-in-class products to treat sleep apnea, announced that John Frank was elected to its Board of Directors. Mr. Frank has over three decades of experience and a successful track record of developing innovative solutions and world-class organizations […]
Sommetrics announced the launch of the pivotal clinical trial of its aerSleep® II device for the treatment of obstructive sleep apnea (OSA). This study is being conducted at 10 university and community-based sleep centers in the U.S. under an Investigational Device Exemption approved by the Food and Drug Administration. Termed the […]
As the world faces a new era of emerging and re-emerging infectious diseases, new technologies are paving the way for safer, more effective treatment options. The Self-Contained Negative Pressure Environment (SCONE™) is a new technology developed by SCONE Medical Solutions Inc. (SMS) in collaboration with Mayo Clinic for infectious disease containment in […]
Sommetrics, a private company developing products and services to improve sleep health, has announced its lead sleep apnea product, aerSleep II, has received FDA Breakthrough Device designation. This program allows for additional FDA feedback to sponsors during the pre-marketing phase but does not alter the basic requirements for market authorization. […]
